Search Results - "Hefti, Franz"

Pharmacology of nerve growth factor and discovery of tanezumab, an anti-nerve growth factor antibody and pain therapeutic by Hefti, Franz

“…The pharmacology of Nerve Growth Factor (NGF) and the discovery and development of tanezumab, a monoclonal anti-NGF antibody for the treatment of pain…”
Get full text

Requirements for a lead compound to become a clinical candidate by Hefti, Franz F

“…A drug candidate suitable for clinical testing is expected to bind selectively to the receptor site on the target, to elicit the desired functional response of…”
Get full text

Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics by Goure, William F, Krafft, Grant A, Jerecic, Jasna, Hefti, Franz

“…Levels of amyloid-beta monomer and deposited amyloid-beta in the Alzheimer's disease brain are orders of magnitude greater than soluble amyloid-beta oligomer…”
Get full text

Novel class of pain drugs based on antagonism of NGF by Hefti, Franz F., Rosenthal, Arnon, Walicke, Patricia A., Wyatt, Sean, Vergara, German, Shelton, David L., Davies, Alun M.

“…Nerve growth factor (NGF) was identified originally as a survival factor for sensory and sympathetic neurons in the developing nervous system. In adults, NGF…”
Get full text

Conformation as the Therapeutic Target for Neurodegenerative Diseases by Krishnan, Rajaraman, Hefti, Franz, Tsubery, Haim, Lulu, Michal, Proschitsky, Ming, Fisher, Richard

“…Therapeutic strategies that target pathways of protein misfolding and the toxicity of intermediates along these pathways are mainly at discovery and early…”
Get more information

Florbetapir F-18: A Histopathologically Validated Beta-Amyloid Positron Emission Tomography Imaging Agent by Lister-James, John, PhD, Pontecorvo, Michael J., PhD, Clark, Chris, MD, Joshi, Abhinay D., PhD, Mintun, Mark A., MD, Zhang, Wei, PhD, Lim, Nathaniel, PhD, Zhuang, Zhiping, PhD, Golding, Geoff, PhD, Choi, Seok Rye, PhD, Benedum, Tyler E., PhD, Kennedy, Paul, PhD, Hefti, Franz, PhD, Carpenter, Alan P., PhD, Kung, Hank F., PhD, Skovronsky, Daniel M., MD, PhD

“…Florbetapir F-18 is a molecular imaging agent combining high affinity for β-amyloid, pharmacokinetic properties that allow positron emission tomography (PET)…”
Get full text

Molecular Basis for Catecholaminergic Neuron Diversity by Grimm, Jan, Mueller, Anne, Hefti, Franz, Rosenthal, Arnon, Bargmann, Cornelia I.

“…Catecholaminergic neurons control diverse cognitive, motor, and endocrine functions and are associated with multiple psychiatric and neurodegenerative…”
Get full text

Pharmacology of neurotrophic factors by Hefti, F

“…The field of neurotrophic factor pharmacology emerged during the past decade with the discovery that these proteins can counteract neuronal atrophy and death…”
Get full text

Multimodal image coregistration and inducible selective cell ablation to evaluate imaging ligands by Virostko, John, Henske, Joseph, Vinet, Laurent, Lamprianou, Smaragda, Dai, Chunhua, Radhika, Aramandla, Baldwin, Ronald M, Ansari, Mohammad S, Hefti, Franz, Skovronsky, Daniel, Kung, Hank F, Herrera, Pedro L, Peterson, Todd E, Meda, Paolo, Powers, Alvin C

“…We combined multimodal imaging (bioluminescence, X-ray computed tomography, and PET), tomographic reconstruction of bioluminescent sources, and two unique,…”
Get full text

First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain by Walicke, Patricia A., Hefti, Franz, Bales, Roxanne, Lu, Shiao-Ping, Ruckle, Jon L., Brown, Mark T., West, Christine R., Shelton, David L.

“…The neurotrophin nerve growth factor has a demonstrated role in pain transduction and pathophysiology. Two randomized, double-blind, placebo-controlled, phase…”
Get full text

Igf1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons by Beck, Klaus D, Powell-Braxtont, Lyn, Widmer, Hans-R, Valverde, Janet, Hefti, Franz

“…Homozygous Igf1 −1− mice at 2 months of age had reduced brain weights, with reductions evenly affecting all major brain areas. The gross morphology of the CNS…”
Get full text

K-252 compounds: modulators of neurotrophin signal transduction by Knüsel, B, Hefti, F

“…K-252 compounds, which share a common polyaromatic aglycon structure, are rather general and potent inhibitors of various protein kinases, including protein…”
Get more information

Regulatory issues in aging pharmacology by Hefti, Franz F., Bales, Roxanne

“…Summary Many current drugs increase the average lifespan by preventing fatal diseases or by slowing down the progressive degenerative diseases that increase…”
Get full text

Caspase Inhibitors Attenuate 1-Methyl-4-Phenylpyridinium Toxicity in Primary Cultures of Mesencephalic Dopaminergic Neurons by Bilsland, James, Roy, Sophie, Xanthoudakis, Steve, Nicholson, Donald W, Han, Yongxin, Grimm, Erich, Hefti, Franz, Harper, Sarah J

“…Parkinson's disease is characterized by a loss of dopaminergic nigrostriatal neurons. This neuronal loss is mimicked by the neurotoxin…”
Get full text

Regulated Release and Polarized Localization of Brain-Derived Neurotrophic Factor in Hippocampal Neurons by Goodman, Laurie J., Valverde, Janet, Lim, Filip, Geschwind, Michael D., Federoff, Howard J., Geller, Alfred I., Hefti, Franz

“…The site and regulation of neurotrophic factor release from neurons is poorly understood. We used a combination of model cell lines and primary culture systems…”
Get full text

Gene Therapy for Parkinson's Disease Associated with GBA1 Mutations by Abeliovich, Asa, Hefti, Franz, Sevigny, Jeffrey

“…Human genetic studies as well as studies in animal models indicate that lysosomal dysfunction plays a key role in the pathogenesis of Parkinson's disease…”
Get more information

Phase III trial results for the amyoid PET imaging agent Florbetapir F 18 (18 F-AV-45): imaging to histopathologic correlations in an end-of-life human subject study by Clark, Christopher M, Schneider, Julie A, Mintun, Mark M.A, Bedell, Barry J, Beach, Thomas G, Sadowsky, Carl H, Doraiswamy, P.M, Gamez, Jose, Sabbagh, Marwan N, Fleisher, Adam S, Schaerf, Frederick, Waseem, Malika, Pontecorvo, Michael J, Hefti, Franz F, Skovronsky, Daniel M

Get full text

(18)F-AV-133: A Selective VMAT2-binding Radiopharmaceutical for PET Imaging of Dopaminergic Neurons by Hefti, Franz F, Kung, Hank F, Kilbourn, Michael R, Carpenter, Alan P, Clark, Christopher M, Skovronsky, Daniel M

“…The early detection and monitoring of neurodegenerative diseases, including Parkinson disease, Alzheimer disease, dementia with Lewy bodies and other…”
Get full text

The non‐peptidyl fungal metabolite L‐783,281 activates TRK neurotrophin receptors by Wilkie, Neil, Wingrove, Peter B., Bilsland, James G., Young, Lisa, Harper, Sarah J., Hefti, Franz, Ellis, Semantha, Pollack, Scott J.

“…Neurotrophin binding to the extracellular surface of the Trk family of tyrosine kinase receptors leads to the activation of multiple signalling cascades,…”
Get full text

Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy by Gao, W Q, Dybdal, N, Shinsky, N, Murnane, A, Schmelzer, C, Siegel, M, Keller, G, Hefti, F, Phillips, H S, Winslow, J W

“…Cisplatin, a widely used chemotherapeutic agent, induces a sensory neuropathy with selective loss of vibration sense and proprioception. Here we demonstrate…”
Get more information